GLP-1 Drugs Are a Class Benefit Now. Bank of America Just Made That Plain.
SSC News Desk Bank of America spends $250 million a year covering Ozempic and Wegovy for its employees and calls it a good investment. Sixty percent of US employers still only cover the drugs for diabetes. The gap between those two sentences is the story. Bank of America spends more than $250 million annually covering GLP-1 drugs —…